Shire sells eight 'non-core' products for $213 million

Share this article:

Shire said today that it is selling eight “non-core” products to Spanish company Almirall for $213 million.

“The divested products are no longer core to Shire's strategy of building market leading positions in specialty markets,” the company said in a statement.

Shire said its focus is moving forward will be on building its attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal and renal diseases businesses and, with its recent in-licensing of Juvista (human recombinant), to build a new specialty area of regenerative medicine.

There are eight products being sold in the transaction. They include:

* Lodine (etodolac) for treatment of rheumatoid arthritis.

* Colazide (balsalazide) for treatment of mild to active ulcerative colitis.

* Meptid (meptazinol hydrochloride) for treatment of pain.

*Cebutid (flurbiprofen) for treatment of the symptoms of rheumatoid arthritis and osteoarthritis.

*Robaxin (methocarbamol) for relief of pain from muscle injuries, spasms, sprains and strains.

*Mintec (peppermint oil) for the relief of discomfort associated with irritable bowel syndrome.

*Solaraze (diclofenac sodium) is a topical preparation for the treatment of actinic keratoses.

*Vaniqa (eflornithine) is a topical prescription medicine for treating unwanted facial hair in women.
 
Almirall chairman and CEO Jorge Gallardo said in a statement the acquisition would expand his company's international presence and “reinforces our position as one of the key European specialty pharmaceutical companies.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.